CD4 and COVID-19: Increasing evidence supports a role for CD4 T-cells in the control and resolution of acute COVID-19 infection [85] and therefore any pre-existing CD4 T-cell depletion as described in patients with haematological malignancy [86] could be a potential barrier to COVID-19 immunity, hampering antiviral responses [87] and the development of immunological memory.